<- Go Home

Sartorius Stedim Biotech S.A.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has collaboration with Bio Usawa Biotechnology, Ltd. focus on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Market Cap

EUR 18.1B

Volume

67.3K

Cash and Equivalents

EUR 298.7M

EBITDA

EUR 761.8M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

EUR 1.3B

Profit Margin

45.64%

52 Week High

EUR 239.80

52 Week Low

EUR 148.75

Dividend

0.37%

Price / Book Value

4.91

Price / Earnings

68.62

Price / Tangible Book Value

-50.70

Enterprise Value

EUR 20.4B

Enterprise Value / EBITDA

26.17

Operating Income

EUR 515.4M

Return on Equity

6.62%

Return on Assets

4.06

Cash and Short Term Investments

EUR 298.7M

Debt

EUR 2.6B

Equity

EUR 4.1B

Revenue

EUR 2.9B

Unlevered FCF

EUR 371.1M

Sector

Life Sciences Tools and Services

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches